Literature DB >> 3855651

Cell lineage heterogeneity in blast crisis of chronic myeloid leukaemia.

P Bettelheim, D Lutz, O Majdic, E Paietta, O Haas, W Linkesch, E Neumann, K Lechner, W Knapp.   

Abstract

Blast cells from 45 patients with chronic myeloid leukaemia in blast crisis (CML-BC) were immunologically phenotyped with a panel of 26 monoclonal antibodies and studied for terminal deoxynucleotidyl transferase (TdT) content. Out of 45 blast-populations, 28 showed a myeloid, 14 a lymphoid, two a mixed and one an unclassifiable marker profile. In contrast to acute myeloid leukaemia (AML), we found frequent involvement of the thrombopoietic and erythropoietic systems in myeloid CML-BC. Furthermore, the marker profile on blast cells in myeloid CML-BC was different from that seen in AML. The blast cells in lymphoid blast crises of CML displayed the same lymphoid marker profile as those in acute lymphoblastic leukaemia. In three of 16 patients who were serially tested, we observed phenotypic changes in the blast cell populations. In one patient the blasts changed from lymphoid to myeloid type while remaining TdT-positive; in another case the blasts switched from granulomonocytic TdT-negative to granulomonocytic TdT-positive. In the third patient erythroid precursor cells appeared as the disease progressed. The results indicate the capacity of blast populations in CML-patients during blast crisis to differentiate along several pathways.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3855651     DOI: 10.1111/j.1365-2141.1985.tb07326.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  Simultaneous occurrence of t(14;18) and t(8;22) common acute lymphoblastic leukemia.

Authors:  C Marosi; P Bettelheim; A Chott; U Köller; G Kreiner; G Steger; U Jäger; H Pirc-Danoewinata; K Lechner
Journal:  Ann Hematol       Date:  1992-02       Impact factor: 3.673

2.  Development of acute leukaemia after idiopathic myelofibrosis.

Authors:  J M Hernández; J F San Miguel; M González; A Orfao; M C Cañizo; C Bascones; J Hernández; A López Borrasca
Journal:  J Clin Pathol       Date:  1992-05       Impact factor: 3.411

3.  Burkitt-like blast crisis in chronic myeloid leukemia.

Authors:  M Colovic; G Jankovic; V Lazarevic; V Lazrevic
Journal:  Med Oncol       Date:  1996-06       Impact factor: 3.064

4.  Correlation of surface marker expression with morphologically and immunologically defined subclasses of acute myeloid leukaemias.

Authors:  H G Drexler; M Menon; M Klein; N Bhoopalam; H L Messmore; J Minowada
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

5.  Disseminated intravascular coagulation and decrease in fibrinogen levels induced by vincristine/prednisolone therapy of lymphoid blast crisis of chronic myeloid leukemia.

Authors:  G Sunder-Plassmann; W Speiser; C Korninger; M Stain; P Bettelheim; I Pabinger-Fasching; K Lechner
Journal:  Ann Hematol       Date:  1991-05       Impact factor: 3.673

6.  Immunophenotypic characterisation of acute leukaemia after polycythemia vera.

Authors:  J M Hernández; A Orfao; M González; B Cuesta; M C López-Berges; M C Cañizo; J Ciudad; J F San Miguel
Journal:  J Clin Pathol       Date:  1993-07       Impact factor: 3.411

Review 7.  Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts.

Authors:  Christian Sillaber; Matthias Mayerhofer; Hermine Agis; Verena Sagaster; Christine Mannhalter; Wolfgang R Sperr; Klaus Geissler; Peter Valent
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

8.  The nature of blast cells in myelodysplastic syndromes evolving to acute leukaemia.

Authors:  J F San Miguel; M González; M C Cañizo; J P Anta; J Hernández; F Ortega; L Borrasca
Journal:  Blut       Date:  1986-06

9.  The structure of the human CD2 gene and its expression in transgenic mice.

Authors:  G Lang; D Wotton; M J Owen; W A Sewell; M H Brown; D Y Mason; M J Crumpton; D Kioussis
Journal:  EMBO J       Date:  1988-06       Impact factor: 11.598

Review 10.  Treatment selection after imatinib resistance in chronic myeloid leukemia.

Authors:  Elias Jabbour; Jorge Cortes; Hagop Kantarjian
Journal:  Target Oncol       Date:  2009-01-30       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.